ProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate Highlights
ProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate Highlights
ProMIS Neurosciences Invited to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference
ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights
Promis Neurosciences (PMN) to Release Earnings on Monday
ProMIS Neurosciences to Present Data on ALS & Parkinsons Disease Programs at Alzheimer's Disease/Parkinson's Disease 2026 International Conference (AD/PD™)
Ally Bridge Group NY LLC Increases Holdings in Promis Neurosciences $PMN
Promis Neurosciences (NASDAQ:PMN) Given Consensus Rating of “Moderate Buy” by Brokerages
ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing
Promis Neurosciences (NASDAQ:PMN) Receives Average Rating of “Moderate Buy” from Brokerages
ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer's Disease
ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer's Disease
ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk
ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer's trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310
ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference
Promis Neurosciences (NASDAQ:PMN) Receives Average Rating of “Moderate Buy” from Analysts
ProMIS Neurosciences Announces Reverse Stock Split
ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights
ProMIS Neurosciences to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
ProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul Alex, Pharm.D., President and Portfolio Manager, Public Equity of Ally Bridge Group
ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer's Trial of PMN310
ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights
ProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer's Association International Conference
ProMIS Neurosciences Announces Private Placement Financing
ProMIS Neurosciences Announces Private Placement Financing
ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer's Disease
ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer's Disease
ProMIS Neurosciences Presents at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
ProMIS Neurosciences Announces First Quarter 2025 Financial Results
ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights
ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer's Disease/Parkinson's Disease 2025 International Conference
ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting
ProMIS Neurosciences to Participate in the 37th Annual Roth Conference
ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer's Disease
ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech Conference
ProMIS Neurosciences Issues Letter to Shareholders
ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights
ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer's Disease Conference
ProMIS Neurosciences to Showcase PMN310's Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences
ProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024
ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer's Association International Conference
ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial
ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing
ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights
ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies
ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS
ProMIS Neurosciences to Present in Upcoming Investor Conferences in April
ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights